CryoLife Announces First Implant of Cryopreserved Osteoarticular Allograft
Advertisement
CryoLife, Inc. announced that a patient received the first Cryopreserved osteoarticular (OA) allograft transplant for resurfacing articular cartilage in the knee. The OA allograft is a section of bone with overlying cartilage derived from the end of the femur, in this case from the femoral condyle.
Patients suffering from a damaged articular surface of the femoral bone usually experience pain and limited mobility that can hinder normal activities. During surgery, the patient's damaged articular surface is removed and replaced with CryoLife's OA allograft, restoring the articular surface.
Dr. Philip A. Davidson, of Tampa Bay Orthopaedic Specialists in St. Petersburg, Florida, performed the surgery. "Prior to this new cryopreservation technology, OA grafts had limited shelf-life and were generally made available for implant with less than two weeks before expiration (45 days). More patients can benefit from these precious grafts as cryopreservation allows for enhanced logistics, improved availability and optimal size and shape matching of these grafts. By introducing these Cryopreserved OA grafts, I believe CryoLife can improve the lives of many of my patients."
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Novartis merges with Alcon - Novartis Board of Directors unanimously approves merger for a value of USD 168 per Alcon share totaling USD 12.9 billion, comprising share consideration of up to 2.8 Novartis shares and a contingent cash payment
Researchers predict cell conversion factors - Potential for regenerative medicine
Category:Neuroprosthetics
Low-level arsenic exposure before birth associated with early puberty and obesity
Marshall-Smith_syndrome
An intestinal chip model takes research of fungal infections to a new level - Successful cooperation between science, clinic and start-up
Hodulcine